Ophthalmologic Manifestations of Kaposi Sarcoma
- Author: Jacqueline Freudenthal, MD; Chief Editor: Hampton Roy, Sr, MD more...
In 1872, Kaposi was the first to report an idiopathic, multiple-pigmented sarcoma of the skin that predominantly affected elderly men of Mediterranean or Ashkenazi ancestry.
Transplant-related Kaposi sarcoma has been reported in patients with renal transplants on immunosuppressive therapy.
Epidemic Kaposi sarcoma, better known as AIDS-related Kaposi sarcoma, commonly affects homosexual males with AIDS.[2, 3, 4, 5]
Whether the 4 variants of Kaposi sarcoma represent the same disease process or different processes that manifest the same end-stage lesion is unclear.
Although the etiology has not been elucidated, the human herpesvirus 8 (HHV-8) or Kaposi sarcoma–associated herpesvirus (KSHV) has been implicated. Chang et al identified this virus in more than 90% of patients with AIDS-related Kaposi sarcoma. KSHV is also the etiological agent of 3 other AIDS-related lymphoproliferative disorders: (1) primary effusion lymphoma, (2) the plasma-cell variant of multicentric Castleman disease, and (3) the vascular tumor recurrent angiolymphoid hyperplasia with eosinophilia.
The life cycle of KSHV consists of a latent and a lytic replication phase. During latent infection, only a limited number of KSHV genes are expressed. The switch between the latent form and lytic replication is regulated by epigenetic factors. Reactive oxygen species hydrogen peroxide also mediates KSHV reactivation from latency. However, induction of lytic replication by environmental stimuli or chemical agents is important for the spread of KSHV, the persistence of infection, the evasion of host immune response, and induction of KSHV-related malignancies (by modification of the host genome).
Kaposi sarcoma is most likely caused by multiple factors, including deregulated expression of oncogenes and oncosuppressor genes by KSHV/HHV-8 combined with decreased immune surveillance and the release of cytokines (viral interleukin [vIL]–6) and growth factors, by HIV acting on infected cells.
vIL-6 is a product of KSHV expressed in latently infected cells and to a higher degree during viral replication. Secretion of vIL-6 is generally poor, but vIL-6 has the potential to induce a wide range of biological effects, such as inducing vascular endothelial growth factor.
KSHV/HHV-8 mediates oncogenesis, although the exact mechanisms by which this happens has not yet been fully elucidated; numerous KSHV/HHV-8 viral oncogenes may contribute to neoplasia formation.[11, 12]
Prior to 1981, fewer than 25 reported cases of ophthalmic Kaposi sarcoma existed in the literature. Currently, the overwhelming majority of ophthalmic Kaposi sarcoma is AIDS related. In 1986, the Centers for Disease Control and Prevention (CDC) reported that Kaposi sarcoma occurs in approximately 24% of patients with AIDS and in 35% of all homosexual men with AIDS. The CDC reported that during the period from 1992-1997, Kaposi sarcoma occurred in 23.8% of males with AIDS and in 27.4% of all homosexual men with AIDS. During the same period, only 2.3% of women with AIDS developed Kaposi sarcoma.
Ophthalmic involvement occurs in 20-24% of patients with AIDS-related Kaposi sarcoma. Ophthalmic presentation was the initial manifestation of AIDS-related Kaposi sarcoma in 4-12% of patients. Eye lesions are neither an early nor a late manifestation of Kaposi sarcoma. A review of the literature reports that most eye lesions involve the conjunctivae or eyelids; 10-75% of patients have conjunctival lesions, and 25-80% of patients have eyelid lesions.
In recent years, the incidence of Kaposi sarcoma among HIV patients has significantly declined, from 60.6% in 1992 to 19.7% in 1997. The exact cause for this decline is unclear, but the introduction of protease inhibitors, combination HIV therapy, and safer sexual practices may have played significant roles.
Kaposi sarcoma is linked to significant morbidity and mortality; it can disseminate to visceral organs (ie, lungs, liver, adrenal glands, kidneys, bone marrow, GI tract) and possibly cause bowel obstruction, lower extremity edema, shortness of breath, hemorrhage, and pain. Visceral and lung involvement usually portends a poor prognosis.
Generally, ophthalmic Kaposi sarcoma is indolent. Ocular tumor growth can result in severe damage to the ocular adnexa, the ocular surface, and even the orbit and choroid.
Involvement of the eyelids can cause significant disfigurement and lid dysfunction. Trichiasis can develop from mechanical ectropion or entropion. Lagophthalmos and trichiasis can result in profound irritation and dryness, infections, and corneal scarring. Large lid tumors can induce irregular corneal astigmatism. Conjunctival involvement may result in recurrent subconjunctival hemorrhages and may even be associated with squamous cell carcinoma in patients with HIV infection. Ultimately, vision could be lost from lid dysfunction, corneal surface changes, or visual obstruction.
Classic Kaposi sarcoma usually involves elderly men with Mediterranean or Ashkenazi ancestry. Endemic Kaposi sarcoma usually involves young black males from central Africa. Transplant-related or AIDS-related Kaposi sarcoma has no racial predilection.
Classic Kaposi sarcoma usually involves elderly men. Endemic Kaposi sarcoma usually involves young males. AIDS-related Kaposi sarcoma predominantly involves homosexual males.
Classic Kaposi sarcoma affects the older population. Endemic Kaposi sarcoma affects children with a male-to-female ratio of 1:1; after puberty, males are predominantly affected. AIDS-related Kaposi sarcoma usually affects males aged 20-49 years.
Kaposi M. Idiopathisches multiple Pigment-sarkom der Haut. Arch Dermatol. Syphilol. 1872:4. [Medline].
Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999 Apr 16. 48(2):1-22. [Medline].
Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 1982 Apr. 93(4):393-402. [Medline].
Mowatt L. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era. West Indian Med J. 2013. 62(4):305-12. [Medline].
Becker KN, Becker NM. Ocular manifestations seen in HIV. Dis Mon. 2014 Jun. 60(6):268-75. [Medline].
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16. 266(5192):1865-9. [Medline].
Ye F, Zhou F, Bedolla RG, Jones T, Lei X, Kang T, et al. Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011 May. 7(5):e1002054. [Medline]. [Full Text].
Centers for Disease Control and Prevention. Update: AIDS--United States, 2000. JAMA. 2002 Aug 14. 288(6):691-2. [Medline].
Mansour AM. Adnexal findings in AIDS. Ophthal Plast Reconstr Surg. 1993 Dec. 9(4):273-9. [Medline].
Gigase PL, de Muynck A, de Feyter M. Kaposi's sarcoma in Zaire. IARC Sci Publ. 1984. 549-57. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Ocular adnexal Kaposi's sarcoma in acquired immunodeficiency syndrome. Am J Ophthalmol. 1990 Nov 15. 110(5):500-3. [Medline].
Meyers D. Eye signs that alert the clinician to a diagnosis of AIDS. SADJ. 2005. 60:386-387. [Medline].
Emina MO, Odjimogho SE. Ocular problems in HIV and AIDS patients in Nigeria. Optom Vis Sci. 2010 Dec. 87(12):979-84. [Medline].
[Guideline] Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009 Sep 4. 58:1-166. [Medline]. [Full Text].
Brasnu E, Wechsler B, Bron A, et al. Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol. 2005 Oct. 140(4):746-8. [Medline].
Hummer J, Gass JD, Huang AJ. Conjunctival Kaposi's sarcoma treated with interferon alpha-2a. Am J Ophthalmol. 1993 Oct 15. 116(4):502-3. [Medline].
Qureshi YA, Karp CL, Dubovy SR. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea. 2009 Sep. 28(8):941-3. [Medline].
Hermans P. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS. Biomed Pharmacother. 1998. 52(10):440-6. [Medline].
Samaniego F, Bryant JL, Liu N, et al. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst. 1999 Jan 20. 91(2):135-43. [Medline].
Simonart T, Noel JC, Andrei G, et al. Iron as a potential co-factor in the pathogenesis of Kaposi's sarcoma?. Int J Cancer. 1998 Dec 9. 78(6):720-6. [Medline].
Hermans P, Clumeck N, Picard O, et al. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. J Hum Virol. 1998 Jan-Feb. 1(2):82-9. [Medline].
Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol. 1995 Aug. 13(8):1966-74. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Treatment of ocular adnexal Kaposi's sarcoma in acquired immune deficiency syndrome. Ophthalmology. 1992 Jul. 99(7):1127-32. [Medline].
Korn BS, Park DJ, Kikkawa DO. Intralesional mitomycin-C for the treatment of conjunctival Kaposi sarcoma. Ophthal Plast Reconstr Surg. 2011 Jul-Aug. 27(4):e88-90. [Medline].
Shuler JD, Holland GN, Miles SA, et al. Kaposi sarcoma of the conjunctiva and eyelids associated with the acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jun. 107(6):858-62. [Medline].
Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug. 14(8):2353-64. [Medline].
Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997 Feb. 15(2):653-9. [Medline].
Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998 Mar. 16(3):1112-21. [Medline].